Sumitomo Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Sumitomo Pharma CEO'su Toru Kimura, Jan2016 tarihinde atandı, in görev süresi 8.83 yıldır. şirketin hisselerinin 0.02% doğrudan sahiptir ve bu hisselerin değeri $ 310.93K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 3.9 yıldır.

Anahtar bilgiler

Toru Kimura

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	8.8yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	2.2yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

CEO

Toru Kimura (64 yo)

8.8yrs

Görev süresi

Mr. Toru Kimura, Ph D., is Representative Director, President & CEO of Sumitomo Pharma Co. Ltd. from June 25, 2024.Mr. Toru serves as Director at Sumitomo Pharma America, Inc. since 2024. He served as Rep...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Toru Kimura	Representative Director	8.8yrs	Veri yok	0.020% $ 310.9k
Motoyuki Sakai	Representative Director and Executive VP of Corporate Planning	less than a year	Veri yok	Veri yok
Hiroyuki Baba	Mngg Exec. Officer of Global Data Design	7.6yrs	Veri yok	0.0015% $ 23.9k
Naoki Noguchi	Executive Officer of Corporate Governance & Communications	2.6yrs	Veri yok	Veri yok
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4.4yrs	Veri yok	0.0038% $ 59.9k
Koichi Kozuki	E.O. of R. Aff.	1.8yrs	Veri yok	Veri yok
Shigeyuki Nishinaka	Managing Executive Office	7.6yrs	Veri yok	0.0020% $ 31.8k
Isao Shimizu	Executive Officer	1.8yrs	Veri yok	Veri yok
Kenji Ueno	Executive Officer	1.8yrs	Veri yok	Veri yok
Hideyuki Harada	Managing Exe. Officer of Tech. R&D Div.	3.6yrs	Veri yok	Veri yok
Tsutomu Nakagawa	Executive Officer	1.8yrs	Veri yok	0.00076% $ 12.0k
Yumi Sato	Exe Off of Drug Dev Div	1.8yrs	Veri yok	Veri yok

2.2yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim: DNPU.F 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Toru Kimura	Representative Director	8.4yrs	Veri yok	0.020% $ 310.9k
Motoyuki Sakai	Representative Director and Executive VP of Corporate Planning	less than a year	Veri yok	Veri yok
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4.4yrs	Veri yok	0.0038% $ 59.9k
Tsutomu Nakagawa	Executive Officer	less than a year	Veri yok	0.00076% $ 12.0k
Saeko Arai	Independent Outside Director	6.4yrs	Veri yok	Veri yok
Minoru Usui	Independent Outside Director	3.4yrs	Veri yok	Veri yok
Nobuhiro Endo	Independent Outside Director	5.4yrs	Veri yok	Veri yok
Hiroshi Niinuma	Director	less than a year	Veri yok	Veri yok
Takashi Kutsunai	Full-Time Audit & Supervisory Board Member	6.4yrs	Veri yok	0.0065% $ 103.6k
Yoshio Iteya	Outside Audit & Supervisory Board Member	6.4yrs	Veri yok	Veri yok
Hisayoshi Kashima	Full-Time Audit & Supervisory Board Member	1.4yrs	Veri yok	0.0035% $ 55.8k
Koji Fujimoto	Independent Outside Director	2.4yrs	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DNPU.F 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Sumitomo Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Sumitomo Dainippon Pharma Announces Personnel Changes Including Representative Director and Organizational Realignment

Sumitomo Dainippon Pharma Announces Changes of Representative Directors and Executive Officers, Effective from April 1, 2021

Recent updates

Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025

Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Mitsui & Co., Ltd. (TSE:8031) agreed to acquire Sumitomo Pharma Animal Health Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Sumitomo Pharma Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. Provides Impairment Loss Guidance for the Second Quarter of the Fiscal Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

Sumitomo Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. to Report Q1, 2023 Results on Jul 29, 2022

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Sumitomo Dainippon Pharma Announces Personnel Changes Including Representative Director and Organizational Realignment

Sumitomo Dainippon Pharma Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Sumitomo Dainippon Pharma Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2022

Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888

Poxel and Sumitomo Dainippon Pharma Announce Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

Poxel SA and Sumitomo Dainippon Pharma Co., Ltd. Announces Approval of TWYMEEG for Treatment of Type 2 Diabetes in Japan

Myovant Sciences and Pfizer Inc. Receives FDA Approval for MYFEMBREE

Sumitomo Dainippon Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2022

Sumitomo Dainippon Pharma Co., Ltd Announces That They Will Initiate A Phase 1 Clinical Study of Dsp-0038 in the United States for the Treatment of Alzheimer’S Disease Psychosis

Sumitomo Dainippon Pharma Co., Ltd. Revises Earnings Guidance for the Year 2022

Sumitomo Dainippon Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2021

Sumitomo Dainippon Pharma Announces Changes of Representative Directors and Executive Officers, Effective from April 1, 2021

Sumitomo Dainippon Pharma Co., Ltd. Revises Earnings Guidance for the Year Ending March 31, 2021

Sumitomo Dainippon Pharma Announces Topline Results of Phase 3 Study on Napabucasin Fails to Reach Primary Endpoints in Colorectal Cancer

Sumitomo Dainippon Pharma Co., Ltd. to Report Fiscal Year 2021 Results on May 12, 2021

Sumitomo Dainippon Pharma Co., Ltd. to Report Q3, 2021 Results on Jan 28, 2021

Sumitomo Dainippon Pharma Co., Ltd. to Report Q2, 2021 Results on Oct 28, 2020

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş